Grünenthal, a leading pharmaceutical company specializing in pain research and management, has announced significant investments in its Latin American production sites. The company has invested over €80 million to enhance its production capabilities in the region, reaffirming its commitment to long-term competitiveness and ensuring a reliable supply of medicines for patients globally.
No responses yet